Mirador Therapeutics Secures $250M in Series B Funding for Precision Medicine Development

March 2024. San Diego. A crew that already sold one precision medicine dream to Merck for $10.8 billion decides retirement is overrated. Mirador Therapeutics shows up with over $400 million in Series A capital and a very specific memory of what it takes to win in immune-mediated disease. Mark C. McKenna does not do nostalgia plays. After building Prometheus Biosciences into a category-defining precision story, he brings the band back together to chase unfinished business. Same city, sharper tools, bigger data, less patience for guesswork.

Fast forward not even two years and Mirador Therapeutics stacks another $250 million in a Series B, pushing total funding past $650 million. New capital from T. Rowe Price Investment Management, Adage Capital Partners, and Fidelity Management and Research Company joins a roster that already reads like a master class in life sciences conviction. ARCH Venture Partners, OrbiMed, Fairmount, Point72, Farallon, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Woodline Partners LP, and Venrock Healthcare Capital Partners did not come back for vibes. They came back for velocity, signal, and a team that has already proved it can turn molecular insight into real outcomes.

Mirador Therapeutics is not guessing its way through immunology. The Mirador360 precision development engine pulls from 2.5M+ patient molecular profiles, aligning human genetics with machine learning to see immune-mediated inflammatory and fibrotic disease for what it actually is. Complex, personal, and overdue for accuracy. Crohn's disease, ulcerative colitis, rheumatoid arthritis, idiopathic pulmonary fibrosis. These are not small swings. They are disciplined ones, aimed at a market that sits as the second-largest drug spend in the United States while still leaving millions of patients underserved.

The leadership room tells you everything. Olivier Laurent, Ph.D. driving science with the same rigor that powered Prometheus. Allison Luo, M.D. bringing clinical judgment that respects patients as data with context. William J. Sandborn, M.D. shaping strategy with decades in gastroenterology and company building. Jordan Zwick, Vika Brough, Tim Andrews, Nori Ebersole, Chris Schaumburg each filling in the operational edges that turn ambition into execution. The board blends operators and investors who have seen cycles, not headlines.

Ten or more clinical readouts expected by the end of 2027 is not bravado. It is a timetable. Proof of concept across programs is the assignment, not the aspiration. Mirador Therapeutics feels less like a launch and more like a continuation, the kind where experience shortens timelines and precision replaces noise. In a sector that often confuses scale with progress, this one is choosing clarity, speed, and intent, and letting the data do the talking.